Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07420283 · ClinicalTrials.gov registry record · Phase 2
A Study of Brenipatide in Participants With Opioid Use Disorder
A Phase 2 study of Opioid Use Disorder, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 465
- Enrollment target
- 20
- Study locations
NCT07420283: Recruiting Phase 2 study of Opioid Use Disorder, sponsored by Eli Lilly and Company.
NCT07420283 is a Phase 2 study of Opioid Use Disorder that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 465 participants, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07420283, a Phase 2 study of Opioid Use Disorder, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 465 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to see if brenipatide, when compared to placebo, is safe and effective for participants with opioid use disorder, when used with buprenorphine with or without naloxone. The maximum potential duration of study participation for a participant in Part A is approximately 144 weeks, maximum potential duration of study participation for a participant in Part B is approximately 116 weeks. The actual duration will vary for each participant depending on the time of enrollment and the overall rate of study enrollment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Buprenorphine
- DRUG Brenipatide
Study Locations (20)
Florida
- Bradenton Research Center, Inc. - Bradenton
- K2 Medical Research - Daytona Beach - Daytona Beach
- NextPhase Research Florida - Hollywood - Hollywood
- Accel Research Sites - Lakeland Clinical Research Unit - Lakeland
- Life Arc Research Centers - Miami - Miami
- Advanced Research for Health Improvement, LLC - Naples
- Innovative Research Institute - Port Charlotte - Port Charlotte
- Better Years Ahead Medical Center - Tampa
- Neuroscience Research Institute - West Palm Beach - West Palm Beach
California
- Ark Clinical Research - Fountain Valley - Fountain Valley
- Center on Substance Use and Health (CSUH) - San Francisco
- UCSF Weill Institute for Neurosciences - Substance Use Disorders Clinic - Mission Bay - San Francisco
Alabama
- Parkway Medical Center - Birmingham
Arizona
- NoesisPharma - Phoenix - East Shea Boulevard - Phoenix
Arkansas
- Woodland International Research Group - Little Rock
Illinois
- Re:Cognition Health - Chicago - Chicago
Indiana
- Indiana University Health Neuroscience Center - Indianapolis
Kentucky
- University of Kentucky Chandler Medical Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 465 participants |
| Start Date | 2026-02-13 |
| Est. Completion | 2028-02 |
| Phase | Phase 2 |
What NCT07420283 shows while recruiting
NCT07420283 is an interventional study that assigns participants to a tested intervention. The registered 465 participants enrollment target is mid-sized for trials with a published cap, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07420283 names 20 study sites across 10 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT07420283 about?
NCT07420283 is a clinical study titled "A Study of Brenipatide in Participants With Opioid Use Disorder". The purpose of this study is to see if brenipatide, when compared to placebo, is safe and effective for participants with opioid use disorder, when used with buprenorphine with or without naloxone. The maximum potential duration of study participation for a participant in Part A is approximately 14...
What is the current status of trial NCT07420283?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 465 participants. The study started on 2026-02-13. Estimated completion is 2028-02.
What conditions does trial NCT07420283 study?
This clinical trial studies the following conditions: Opioid Use Disorder.
What interventions are being tested in trial NCT07420283?
The interventions under investigation include: Placebo (DRUG), Buprenorphine (DRUG), Brenipatide (DRUG).
Who is sponsoring clinical trial NCT07420283?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07420283 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07420283's enrollment target sits among peer trials
465 39th of 257 higher than 219 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Remotely Observed Methadone Evaluation II
RECRUITING · Phase 2
-
Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl
RECRUITING · Phase 2
-
Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose
RECRUITING · Phase 2
-
Ketamine for Opioid Use Disorder
RECRUITING · Phase 2
-
Brief Digitally-Enhanced Intervention for Reducing Alcohol Use During MOUD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06717698 · 465 participants · Phase 2
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
- NCT05312879 · 466 participants · Phase 2
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
- NCT06917404 · 466 participants · Phase 3
A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
- NCT07055165 · 466 participants · NA
Connect2Care: Prostate Cancer Education and Screenings for African American Men
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI